Drugs that contain Calcium Oxybate; Magnesium Oxybate; Potassium Oxybate; Sodium Oxybate

1. Drug name - XYWAV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963 JAZZ Sensitive drug distribution system and method
Dec, 2022

(6 days from now)

US8731963

(Pediatric)

JAZZ Sensitive drug distribution system and method
Jun, 2023

(6 months from now)

US10195168 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jan, 2033

(10 years from now)

US10675258 JAZZ Method of using gamma-hydroxybutyrate compositions for the treatment of disorders
Jan, 2033

(10 years from now)

US9132107 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(10 years from now)

US8591922 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(10 years from now)

US8901173 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(10 years from now)

US8772306 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US9050302 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US10213400 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US9486426 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US10864181 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US11253494 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US10864181

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US9050302

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US10213400

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US11253494

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US9486426

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US8772306

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US11426373 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 12, 2028
New Product (NP) Jul 21, 2023
New Indication (I) Aug 12, 2024

Market Authorisation Date: 21 July, 2020

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of treating patients with idiopathic hypersomnia with sodium oxybate when divalproex sodium is concomitantly administered; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered; Method of reducing adverse effects in patients who are concomitantly administered a salt of gamma-hydroxybutyrate and divalproex sodium; Method of treating patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb administered between 2 and 4 hours after eating

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in